20 February 2017 Photothermal therapy combined with dinitrophenyl hapten for the treatment of late stage malignant melanoma
Author Affiliations +
Proceedings Volume 10065, Biophotonics and Immune Responses XII; 1006505 (2017) https://doi.org/10.1117/12.2251090
Event: SPIE BiOS, 2017, San Francisco, California, United States
To evaluate the efficacy and safety of photothermal with dinitrophenyl hapten (DNP) for patients with malignant melanoma (MM), Patients with pathology confirmed stage III or IV MM were enrolled. Seventy-two patients were randomized into two groups, DNP alone group (n=36) and DNP plus photothermal therapy group (n=36). The results showed that the patients in the combination treatment group had longer median progression-free survival time (19.0m vs. 12.0m, p=0.007). No severe adverse events were observed in both groups. Thus, the combination of photothermal therapy and DNP maybe a new therapeutic strategy for patients with advanced MM.
© (2017) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Xiaosong Li, Xiaosong Li, Nan Du, Nan Du, Haijun Li, Haijun Li, Shan Long, Shan Long, Dianjun Chen, Dianjun Chen, Feifan Zhou, Feifan Zhou, Yuanyuan Xu, Yuanyuan Xu, Fuli Wang, Fuli Wang, Wei R. Chen, Wei R. Chen, } "Photothermal therapy combined with dinitrophenyl hapten for the treatment of late stage malignant melanoma", Proc. SPIE 10065, Biophotonics and Immune Responses XII, 1006505 (20 February 2017); doi: 10.1117/12.2251090; https://doi.org/10.1117/12.2251090


Laser immunotherapy for advanced solid tumors
Proceedings of SPIE (March 07 2017)
SnET2: clinical update
Proceedings of SPIE (April 02 1996)
Preliminary results of a phase I II clinical trial using...
Proceedings of SPIE (February 24 2010)
Laser photothermal therapy in treatment of mouse melanoma
Proceedings of SPIE (April 15 2005)

Back to Top